Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

NCT00613145 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Refractory Malignancy

Interventions

DRUG: Capecitabine and Sorafenib
DRUG: Capecitabine and Sorafenib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]